复星医药公告,公司控股子公司复宏汉霖收到中国证监会出具的《备案通知书》,其若干名股东将所持合计182,645,856股复宏汉霖境内未上市股份转为境外上市股份并于香港联交所上市流通的申请事项,已完成中国证监会备案。
本文源自:金融界AI电报
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.